Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PVT1 siRNA
- Development stage
- Preclinical
- Lead developer
- Medical College of Wisconsin
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
PVT1 siRNA is a small interfering RNA designed to silence the expression of the long non-coding RNA (lncRNA) PVT1 (plasmacytoma variant translocation 1). PVT1 is an oncogenic lncRNA frequently overexpressed in various cancers, including cervical, breast, and gastric carcinomas. By targeting PVT1 for degradation via the RNA interference (RNAi) pathway, this siRNA inhibits cancer cell proliferation, migration, and invasion while promoting apoptosis and sensitizing cells to chemotherapeutic agents like cisplatin. Mechanistically, PVT1 has been shown to interact with proteins such as Nucleolin to stabilize mRNAs like GADD45A, contributing to tumor progression and chemoresistance.
- Other names
- siRNA targeting PVT1PVT1-targeting siRNAPVT-1-targeting siRNAPVT 1-targeting siRNA
02
Targets
PVT1 (Plasmacytoma variant translocation 1)
Beyond the preview
Go deeper on PVT1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PVT1 siRNA.